Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01482845 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease
A Phase 1 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01482845 is a Phase 1 study that has completed, run by Abbott. The registered enrollment target is 20 participants.
The verdict
NCT01482845, a Phase 1 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
Interventions
- DRUG Placebo
- DRUG ABT-126
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01482845
The ClinicalTrials.gov registry entry for NCT01482845 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01482845 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01482845 about?
NCT01482845 is a clinical study titled "A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease". This study will investigate safety, tolerability and pharmacokinetics of ABT-126 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.
What is the current status of trial NCT01482845?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2011-11. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01482845?
The interventions under investigation include: Placebo (DRUG), ABT-126 (DRUG).
Who is sponsoring clinical trial NCT01482845?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.